INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up.

Autor:	Arevalo JF; Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; †Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina; ‡Instituto de Cirugia Ocular, San Jose, Costa Rica; §Departamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo, São Paulo, Brazil; ¶Consorcio Hospital, General Universitario de Valencia, Valencia, Spain; **Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina; and ††Instituto Docente de Especialidades Oftalmológicas (IDEO), Maracaibo, Venezuela., Lasave AF, Wu L, Maia M, Diaz-Llopis M, Alezzandrini AA, Brito M
Jazyk:	angličtina
Zdroj:	Retina (Philadelphia, Pa.) [Retina] 2017 Feb; Vol. 37 (2), pp. 334-343.
DOI:	10.1097/IAE.0000000000001181
Abstrakt:	Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). Methods: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. Results: The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted. Conclusion: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu